Vivani Medical, Inc. ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it intends to spin off ...

Gilead Sciences has taken a major step towards ... and Zimbabwe. The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies, real-world ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented findings from the REPRIEVE trial about the use of statins among people living with HIV with frailty ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead Sciences (GILD) is one of the stocks most ... During this period, the Zacks Medical - Biomedical and Genetics industry, which Gilead falls in, has gained 1.6%. The key question now is ...

Buy Gilead Sciences (GILD) Stock at 52-Week Highs? Medical pioneer Gilead Sciences has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.

Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

A new study published has revealed that Gilead Sciences’ Lenacapavir has shown promising results as prevention method for HIV with long-lasting effects. The annual injection can be used as a pre ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor ...